First, combination strategies should be explored to assess the synergistic effects of CLL-1-targeted therapies with existing AML treatments, including chemotherapy and other immunotherapies, to enhance efficacy and mitigate resistance. The gene discussed is CLEC12A; the disease is acute myeloid leukemia.